An observational study in Breast Cancer and Radiotherapy, sponsored by Xiaohui Zhao. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Xiaohui Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.
Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 3rd largest by planned enrollment of the 408 observational ones that give a count, is one of 187 that started in 2026, is one of 408 observational ones, reaches primary completion later than 753 of the 1,064 other live ones, and was the 1,929th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,930 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 279 · Phase 2 641 · Phase 3 371 · Phase 4 51
First in 1997; this study’s year is marked. 187 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 51,000 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,520 interventional studies, 241 across the 408 observational. Of the 446 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
488 of 1,930 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xiaohui Zhao as lead sponsor.
Xiaohui Zhao has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
248 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 248 to your calendar (.ics) → With an account.
Among the 1,930 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer remains the most prevalent malignancy among women worldwide, with a continuously increasing incidence. As a crucial component of comprehensive cancer treatment, radiotherapy plays a key role in reducing local recurrence rates and improving overall survival outcomes. However, traditional radiotherapy target volume contouring and treatment planning design rely heavily on clinician expertise, presenting challenges such as prolonged processing time, significant inter-observer variability, and high subjectivity in dose optimization. Although artificial intelligence has made substantial progress in automated contouring and planning, conventional single-modal models still face major limitations. These models struggle to effectively integrate clinical text, tumor biological characteristics, and dose distribution factors, resulting in restricted generalizability. Therefore, developing an intelligent radiotherapy assistance system capable of multimodal data fusion is of high clinical significance to enhance precision and efficiency in breast cancer radiotherapy.
This study aims to develop an innovative breast cancer radiotherapy assistance system based on a multimodal large language model. By integrating multimodal imaging data (including CT, MRI, and ultrasound), pathology reports, and structured electronic health record text, the system realizes end-to-end intelligence from target volume contouring to treatment plan generation. Employing a multicenter, ambidirectional cohort design, the study collects comprehensive clinical data from breast cancer patients who have undergone breast-conserving surgery or mastectomy. Technologically, the system innovatively combines the natural language processing capabilities of large language models with the image analysis strengths of deep learning, utilizing attention mechanisms to achieve deep fusion and interactive comprehension of heterogeneous medical data. Notably, the system breaks through traditional radiotherapy planning workflows by jointly optimizing target contouring and dose planning as a unified pipeline, applying reinforcement learning algorithms to dynamically balance target volume coverage with organ-at-risk protection. The outcomes of this study will provide an important paradigm for the clinical application of AI in radiation oncology and advance the field of precision radiotherapy.
The study population includes patients with breast cancer from multiple medical centers. The retrospective cohort comprises patients treated at Sun Yat-sen Memorial Hospital (n=35,000) and external collaborating centers (Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, n=15,000) between January 1, 2002, and October 31, 2025. The prospective test cohort comprises patients prospectively enrolled at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Retrospective collection of clinical data, multimodal images (MRI, CT, ultrasound, X-ray), pathology reports, and radiotherapy plans from patients with breast cancer treated at Sun Yat-sen Memorial Hospital between January 1, 2002, and October 31, 2025. This cohort (n=35,000) is used for model training and internal validation of the multimodal LLM-assisted automated contouring and radiotherapy planning system.
Other: Multimodal LLM-assisted target volume auto-segmentation and intelligent radiotherapy planning system
Retrospective collection of data from external collaborative centers (Sun Yat-sen Memorial Hospital Shenzhen Hospital, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) between January 1, 2002, and October 31, 2025 (total n=15,000). This cohort is used to evaluate the external generalizability and robustness of the multimodal AI model.
Other: Multimodal LLM-assisted target volume auto-segmentation and intelligent radiotherapy planning system
Prospective collection of data from patients with breast cancer treated at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000). This cohort undergoes double-blind evaluation to prospectively test the performance of the multimodal LLM-driven target volume auto-segmentation and intelligent radiotherapy planning system in clinical practice.
Other: Multimodal LLM-assisted target volume auto-segmentation and intelligent radiotherapy planning system
The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention.
Dice Similarity Coefficient (DSC) of Target Volume Auto-Segmentation
Evaluation of the Dice Similarity Coefficient (DSC) between AI-generated automatic breast cancer target volume contours and expert manual contours.
Time frame: Baseline
95% Hausdorff Distance (95HD) of Target Volume Auto-Segmentation
Evaluation of the 95% Hausdorff Distance (95HD) between AI-generated automatic breast cancer target volume contours and expert manual contours.
Time frame: Baseline
Intersection over Union (IoU) of Target Volume Auto-Segmentation
Evaluation of the Intersection over Union (IoU) between AI-generated automatic breast cancer target volume contours and expert manual contours.
Time frame: Baseline
Clinical Evaluation Score of Target Volume Auto-Segmentation
Blinded evaluation by radiation oncology experts using the Investigator-Developed Cancer Target Volume Contouring Performance Evaluation Scale, a structured 5-point clinical evaluation scale. The scale assesses five dimensions: laterality accuracy (0 to 1 point), radiotherapy type suitability (0 to 1 point), target volume definition (0 to 1.5 points), coverage (0 to 1 point), and structural integrity (0 to 0.5 points). The total score ranges from a minimum of 0 to a maximum of 5, where higher scores indicate better target volume contouring quality and clinical acceptability.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 12 months later.
Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 12 months is below that.
Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.